Dermatitis acneiform – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 12:27:11 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Dermatitis acneiform – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A study testing aprepitant gel for treating skin rash in cancer patients receiving epidermal growth factor receptor inhibitor therapy https://clinicaltrials.eu/trial/a-study-testing-aprepitant-gel-for-treating-skin-rash-in-cancer-patients-receiving-epidermal-growth-factor-receptor-inhibitor-therapy/ Wed, 29 Apr 2026 15:08:12 +0000 https://clinicaltrials.eu/trial/a-study-testing-aprepitant-gel-for-treating-skin-rash-in-cancer-patients-receiving-epidermal-growth-factor-receptor-inhibitor-therapy/ This study is looking at skin problems that can happen when people receive certain cancer treatments called epidermal growth factor receptor inhibitors. These cancer medicines can cause skin reactions that look like acne, with bumps, pimples, and redness, along with itching and burning sensations. The treatment being tested is called HT-001, which is a gel that contains aprepitant and is applied directly to the skin. Some people in the study will receive HT-001 gel while others will receive placebo.

The purpose of this study is to see if HT-001 gel can help reduce these skin problems in people who develop them while taking cancer medicines. The study will also look at how safe the gel is and whether it causes any side effects. The study has two parts: the first part will check how much of the medicine gets into the body when applied to the skin, and the second part will compare different doses of HT-001 gel to placebo to see which works best.

People taking part in the study will use the gel for up to six weeks. During this time, they will have regular visits where doctors will check their skin reactions, ask about itching and pain, and monitor for any side effects. The doctors will take measurements of the skin problems, check vital signs like blood pressure and heart rate, do blood tests, and perform heart monitoring tests. The study will track whether the skin reactions improve, whether people need additional treatments for their skin, and whether they are able to continue their cancer treatment without having to lower the dose or stop because of skin problems.

]]>